•Innovative Biotechnology & Pharmaceutical strategist creating market value through 10+ yrs of growth & industry vision. •Our purpose is to bridge the gap between university and government lab inventions by commercializing them into the marketplace.•We are an executive team of forward-thinking, intelligent, trustworthy industry professionals that desire to collaborate on meaningful business ventures. Our company acquires leading-edge technologies from distinguished institutions such as the University of Notre Dame, MIT, Boeing, NASA, etc.•We look for technologies across multiple industries with strong IP verticals and game-changers for society.•Niche scope of reach to multi cutting-edge technologies and market access allows for solutions-based outcomes for all stakeholders, including patients.•Personalizing patient quality of life is centric to the goals of progressing forward as a global human body. •Protocol designs with fewer amendments, high quality inclusion criteria, global access to patients in variable settings, larger statistical power through data-driven & tailor-made AI algorithms to transparently expose risk, AEs, & side effects profile is key for a robust IND & NDA approval. •Systems & wholistic approach to drug development with RWE & wide-angle view of pharmacovigilance & safety is vital for future FDA approvals. •PV, AE, OTC, DIN, NPN & 21CFR, IND, EOP1, NDA, BLA, CTA, IC, IRB, GCP, GLP, GMP, PhRMA, MDR, SOP, SAE reporting, ICH guidelines, & regulatory auditing.